Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus

International Journal of Cancer

Volumn 109, Issue 4, 2004, Pages 483-490

  Takeuchi, Hiroya ^a   Ozawa, Soji ^a   Shih, Chih Horng ^a   Ando, Nobutoshi ^a   Kitagawa, Yuko ^a   Ueda, Masakazu ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; p53; Prognosis; RB; Transfection

Indexed keywords

GENE PRODUCT; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; VASCULOTROPIN; PROTEIN P16INK4A; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CARCINOMA; FEMALE; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; P16 INK4ALPHA GENE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL LINE; TUMOR VOLUME; DOWN REGULATION; ESOPHAGUS TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1542510119     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11734     Document Type: Article

References (53)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Liotta LA, Kleinerman J, Saidel GM. The significance of heterogeneous tumor cell clumps in the metastatic process. Cancer Res 1976;36:889-94.
4. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-6.
5. Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999;79:316-22.
6. Medri L, Nanni O, Volpi A, Scarpi E, Dubini A, Riccobon A, Becciolini A, Bianchi S, Amadori D. Tumor microvessel density and prognosis in node-negative breast cancer. Int J Cancer 2000;89:74-80.
7. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
8. Senger DR, Galli SJ, Dvorak AM, Perruzi CA, Harvey VS, Dvorak HF. Tumor cells secrete vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
9. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993;194;1234-41.
10. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-8.
11. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63.
12. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997;15:826-32.
13. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997;3:313-9.
14. Murphy KL, Dennis AP, Rosen JM. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 2000;14:2291-302.
15. Moyret-Lalle C, Duriez C, Van Kerckhove J, Gilbert C, Wang Q, Puisieux A. p53 induction prevents accumulation of aberrant transcripts in cancer cells. Cancer Res 2001;61:486-8.
16. Sanchez-Cespendes M, Decker PA, Doffek KM, Esteller M, Westra WH, Alawi EA, Herman JG, Demeure MJ, Sidransky D, Ahrendt SA. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 2001;61:2092-6.
17. INK4a and history-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell cancer. Cancer Res 2001;61:3419-24.
18. Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M, Sakata K, Sato N, Saito K, Satodate R. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 1996;56:3875-8.
19. Ohsawa N, Uchino S, Saito T, Miyahara M, Inoue T, Kitano S. Prognostic significance of loss of heterozygosity on chromosome 9p21-22 in human esophageal cancer. Int J Clin Oncol 1997;2:230-4.
20. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Arii S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998;77:1704-9.
21. Xing EP, Yang GY, Wang LD, Shi ST, Yang CS. Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res 1999;5:1231-40.
22. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225-32.
23. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinoma. Cancer 1989;63:2169-73.
24. Kadowaki T, Shiozaki H., Inoue M. E-cadherin and α-cathenin expression in human esophageal cancer. Cancer Res 1994;54:291-6.
25. Kitagawa Y, Ueda M, Ando N, Shimizu N, Abe O. Significance of int-2/ hst-1 coamplification as a prognostic factors in patients with esophageal squamous cell carcinoma. Cancer Res 1991;51:1504-8.
26. Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M., Kitajima M. Cyclin D1 amplification of cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 1996;2:1155-61.
27. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M., Kitajima M. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997;3:2229-36.
28. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-8.
29. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
30. ink4a/CDKN2 in esophageal squamous cell carcinoma: high BAX and p16 ink4a/CDKN2 identifies patients with good prognosis. J Clin Oncol 2001;19:2272-81.
31. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K, Hamada K. Restoration of wild type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999;59:3783-9.
32. Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, Watanabe H, Sugimura T, Terada M. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 1994;203:1090-5.
33. Enders GH, Koh J, Missero C, Rustgi AK, Harlow E. p16 inhibition of transformed and primary squamous epithelial cells. Oncogene 1996;12:1239-45.
34. Arap W, Nishioka R, Furnari FB, Cavenee WK, Huang HJS. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995;55:1351-4.
35. Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 9th ed. Tokyo: Kanehara Public Co., 1999.
36. Sobin LH, Wittekind CH (eds). 1997 UICC TNM classification of malignant tumors. 5th ed. New York: John Wiley & Sons, 1997.
37. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ. DNA sequences analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
38. kip1 expression is a strong independent prognostic factor of reduced survival in NO gastric carcinoma. Cancer 2000;89:2247-57.
39. Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Mukai M, Ueda M, Kitajima M. Further evidence that altered p16/CDKN2 gene expression is associated with lymph node metastasis in squamous cell carcinoma of the esophagus. Oncol Rep 2001;8:627-32.
40. Güner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M, Daniel PT. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 2003;103:445-54.
41. Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, Kano M. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999;80:1281-8.
42. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Inoue M, Yano M, Kimura Y, Yamamoto M, Monden M. Effect of cyclin D1 and associated proteins on proliferation of esophageal squamous cell carcinoma. Int J Oncol 1998;13:455-60.
43. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001;61:6952-7.
44. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998;58:2288-92.
45. Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM., Pollock RE. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655-61.
46. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4:3017-24.
47. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61:2256-60.
48. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000;78:51-62.
49. Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK, Park CK. Clinical prognostic values of vascular endothelial growth factor, microvessel density, and p53 expression in esophageal carcinomas. J Korean Med Sci 2002;17:201-7.
50. D'Amico M, Wu K, Di Vizio D, Reutens AT, Stahl M, Fu M, Albanese C, Russel RG, Muller WJ, White M, Negassa A, Lee HW, et al. The role of INK4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res 2003;63:3395-402.
51. Shintani M, Okazaki A, Masuda T, Kawada M, Ishizuka M, Doki Y, Weinstein IB, Imoto M. Overexpression of cyclin D1 contributes to malignant properties of esophageal tumor cells by increasing VEGF production and decreasing Fas expression. Anticancer Res 2002;22:639-48.
52. INK4A gene results in down-regulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol Res 2000;12:335-42.
53. Gibson SL, Dai CY, Lee HW, DePinho RA, Gee MS, Lee WMF, Furth EE, Brensinger C, Enders GH. Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res 2003;63:742-6.